Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Laprituximab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crotedumab, an antibody targeting GCGR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cergutuzumab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Afasevikumab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Telisotuzumab, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rosmantuzumab, an antibody targeting RSPO3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lupartumab, an antibody targeting LYPD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Losatuxizumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lesofavumab, an antibody targeting Influenza B Virus.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Duvortuxizumab, an antibody targeting CD19 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Azintuxizumab, an antibody targeting SLAMF7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aprutumab, an antibody targeting FGFR2.